IUC26672-88

Abstract Code: IUC26672-88   Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33) Aspden 1, D. Bimbatti 2, A. Dalla Volta 3, G. Roviello 4, R. Iacovelli 5, G. Bozza 6, M.G. Vitale 7, E. Fantinel 8, A. Guida 9, F.M....

IUC26671-87

Abstract Code: IUC26671-87   Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026 Buchanan 1, G. Clements 1, C. Forde 1, A. Clayton 1 (1) Northern Ireland cancer centre, Belfast – United Kingdom   Objective: Adjuvant...

IUC26666-91

Abstract Code: IUC26666-91   Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC) Winayak 1, X. Li 1, N.J. Salgia 2,...

IUC26658-92

Abstract Code: IUC26658-92   Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations Khanna 1, T. Dey 2, E. Blanchard-Cavagis 3, B....

IUC26657-91

Abstract Code: IUC26657-91   Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study. Zinelli Ronzoni 1, M. Maffezzoli 1, E. Lai 2, E. Verzoni 3, C. Lolli 4, M. Di Napoli 5, A. Signori 6, S. Buti 1, S.E. Rebuzzi 7, D....

IUC26628-89

Abstract Code: IUC26628-89   Real-World Outcomes of Adjuvant Pembrolizumab in Renal Cell Carcinoma: A Single-Centre Experience    Okuma 1, C. Nwankwo 1, M. Cortez 1, M. Chipuriro 1, K. Kumar 1 (1) James Cook University Hospital, Middlesbrough – United...
error: Content is protected !!